Merck reports data from Januvia CVOT

Merck & Co. Inc. (NYSE:MRK) reported results from the TECOS cardiovascular outcomes trial (CVOT) of Januvia sitagliptin, which Merck had previously said met the study's primary endpoint of non-inferiority

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE